Cargando…
Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168576/ https://www.ncbi.nlm.nih.gov/pubmed/37159470 http://dx.doi.org/10.1371/journal.pdig.0000242 |
_version_ | 1785038882586230784 |
---|---|
author | Ravindran, Rizani Szadkowski, Leah Lovblom, Leif Erik Clarke, Rosemarie Huang, Qian Wen Manase, Dorin Parente, Laura Walmsley, Sharon |
author_facet | Ravindran, Rizani Szadkowski, Leah Lovblom, Leif Erik Clarke, Rosemarie Huang, Qian Wen Manase, Dorin Parente, Laura Walmsley, Sharon |
author_sort | Ravindran, Rizani |
collection | PubMed |
description | The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The results were collated and answers were compared between the two age cohorts. Overall, 70% (83% older, 54% younger cohort, no difference by sex) responded to the survey. The overall feedback was positive with over 90% of respondents answering that the website was easy to use. Despite the age gap, both the older cohort and younger cohort reported ease of performing study activities through a personal electronic device. Only 30% of the participants had previously participated in a clinical trial, however over 90% agreed that they would be willing to participate in future clinical research. Some difficulties were noted in refreshing the browser whenever updates to the website were made. The feedback attained will be used to improve current processes and procedures of the STOPCoV trial as well as share learning experiences to inform future fully decentralized research studies. |
format | Online Article Text |
id | pubmed-10168576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101685762023-05-10 Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey Ravindran, Rizani Szadkowski, Leah Lovblom, Leif Erik Clarke, Rosemarie Huang, Qian Wen Manase, Dorin Parente, Laura Walmsley, Sharon PLOS Digit Health Research Article The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The results were collated and answers were compared between the two age cohorts. Overall, 70% (83% older, 54% younger cohort, no difference by sex) responded to the survey. The overall feedback was positive with over 90% of respondents answering that the website was easy to use. Despite the age gap, both the older cohort and younger cohort reported ease of performing study activities through a personal electronic device. Only 30% of the participants had previously participated in a clinical trial, however over 90% agreed that they would be willing to participate in future clinical research. Some difficulties were noted in refreshing the browser whenever updates to the website were made. The feedback attained will be used to improve current processes and procedures of the STOPCoV trial as well as share learning experiences to inform future fully decentralized research studies. Public Library of Science 2023-05-09 /pmc/articles/PMC10168576/ /pubmed/37159470 http://dx.doi.org/10.1371/journal.pdig.0000242 Text en © 2023 Ravindran et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ravindran, Rizani Szadkowski, Leah Lovblom, Leif Erik Clarke, Rosemarie Huang, Qian Wen Manase, Dorin Parente, Laura Walmsley, Sharon Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title | Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title_full | Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title_fullStr | Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title_full_unstemmed | Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title_short | Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey |
title_sort | decentralized study of covid vaccine antibody response (stopcov): results of a participant satisfaction survey |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168576/ https://www.ncbi.nlm.nih.gov/pubmed/37159470 http://dx.doi.org/10.1371/journal.pdig.0000242 |
work_keys_str_mv | AT ravindranrizani decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT szadkowskileah decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT lovblomleiferik decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT clarkerosemarie decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT huangqianwen decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT manasedorin decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT parentelaura decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT walmsleysharon decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey AT decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey |